VCM
BLCM

Vigilant Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Vigilant Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-30
Closed -$3K – 473
2017
Q4 		$3K Hold
30
– – ﹤0.01% 390
2017
Q3 		$3K Hold
30
– – ﹤0.01% 288
2017
Q2 		$4K Buy
+30
New +$3.72K ﹤0.01% 255

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vigilant Capital Management's BLCM Position: Q1 2018 in Review

Vigilant Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2018, closing a stake of 30 shares — an estimated $3K sold.

Vigilant Capital Management first reported a position in BLCM in Q2 2017 and held it in 3 quarters. The position peaked at $4K in Q2 2017. 90 funds tracked by Wall St. Rank hold BLCM as of Q1 2018.

  • Vigilant Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Vigilant Capital Management sold 30 Bellicum Pharmaceuticals, Inc. shares in Q1 2018, an estimated $3K.
  • Vigilant Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • Vigilant Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $4K in Q2 2017.
  • 90 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2018.

Based on Vigilant Capital Management's 13F filing for Q1 2018, filed 4 Apr 2018.